ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 1st Quarter 2024
16 Mai 2024 - 6:00PM
Business Wire
- Consolidated revenue of €1.4 million at the end of March
2024
- Cash position of €2.7 million as of March 31, 2024, before
receipt of Research Tax Credit of €1.4 million
Regulatory News:
ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA
PME), a new generation biotech company dedicated to the
discovery and development of innovative therapies based on the
world’s only natural recombinant apoA-I, today provides an update
on its activity and cash position as of March 31, 2024.
Selected financial information (IFRS)
€m
Q1 2024
Q1 2023
Revenue from biotech activity
0.00
0.00
Revenue from IRIS Pharma
1.40
1.09
Total revenue
1.40
1.09
Other revenue
0.00
0.00
Total revenue income and
revenue
1.40
1.09
Cash and cash equivalents at the end of
the period
2.70
2.90
ABIONYX Pharma recorded consolidated revenue of €1.4 million for
the first quarter of 2024, representing an organic growth of +18%
compared with Q1 2023. This growth is purely organic, as the Group
did not order any studies from IRIS Pharma during the quarter.
Regarding the biotech activities dedicated to the discovery and
development of innovative therapies to improve the lives of
patients, the Company did not generate any revenue in this
financial year, ABIONYX Pharma continuing to provide its bioproduct
free of charge as part of the Compassionate Access Authorization
(CAA) requests.
As of March 31, 2024, the Company had cash and cash equivalents
of nearly €2.7 million, before the estimated €1.4 million Research
Tax Credit.
Following the arrival of Dr Rob Scott as CMO and Head of R&D
in January, the Company is also focusing on the search for
strategic partnerships.
At last, the Company continues to receive new Compassionate
Access Authorisation (CAA) requests for bio-HDL (CER-001) from
several hospitals around the world.
Next financial release:
- Cash position and activity update for Q2 2024, on
August 22, 2024
About ABIONYX Pharma
ABIONYX Pharma is a next-generation biotech company focused on
developing innovative medicines in diseases where there is no
effective or existing treatment, even the rarest ones. The company
expedites the development of novel therapeutics through an
extensive expertise in lipid science and a differentiated apoA-I
-based technology platform. ABIONYX Pharma is committed to
radically improving treatment outcomes in sepsis and critical
care.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240516885167/en/
NewCap Investor relations Nicolas Fossiez Louis-Victor
Delouvrier abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 00 15
Abionyx Pharma (EU:ABNX)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Abionyx Pharma (EU:ABNX)
Historical Stock Chart
Von Jun 2023 bis Jun 2024